Terms: = Germ cell tumor AND PSA AND Prognosis
26 results:
1. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
[TBL] [Abstract] [Full Text] [Related]
2. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract] [Full Text] [Related]
3. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC; Halabi S; Somarelli JA; Humeniuk M; Wu Y; Oyekunle T; Howard L; Huang J; Anand M; Davies C; Patel P; Staats J; Weinhold KJ; Harrison MR; Zhang T; George DJ; Armstrong AJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):762-769. PubMed ID: 35292724
[TBL] [Abstract] [Full Text] [Related]
4. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract] [Full Text] [Related]
5. [Diagnosis and treatment of small cell neuroendocrine carcinoma of the prostate].
Zhang M; Shi W; Zhang QW; Wang W; Li QY
Zhonghua Nan Ke Xue; 2021 Mar; 27(3):219-225. PubMed ID: 34914303
[TBL] [Abstract] [Full Text] [Related]
6. PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite prognosis in Prostate Cancers.
Yang M; Li JC; Tao C; Wu S; Liu B; Shu Q; Li B; Zhu R
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572596
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases.
Bell PD; Huber AR; Agostini-Vulaj D
Diagn Pathol; 2021 Apr; 16(1):35. PubMed ID: 33892760
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
[TBL] [Abstract] [Full Text] [Related]
10. Neuroendocrine Cancer of the Prostate.
Kránitz N; Szepesváry Z; Kocsis K; Kullmann T
Pathol Oncol Res; 2020 Jul; 26(3):1447-1450. PubMed ID: 31414399
[TBL] [Abstract] [Full Text] [Related]
11. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract] [Full Text] [Related]
12. Diagnosis and management of metastatic neoplasms with unknown primary.
Bochtler T; Löffler H; Krämer A
Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical characteristics of 13 neuroendocrine prostate cancer patients].
Zhang WH; Si TG; Yang XL; Yang B; Liu CF; Yu HP; Xing WG; Guo Z
Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1316-1319. PubMed ID: 28482433
[No Abstract] [Full Text] [Related]
14. Uveal melanoma: A pathologist's perspective and review of translational developments.
Schoenfield L
Adv Anat Pathol; 2014 Mar; 21(2):138-43. PubMed ID: 24508696
[TBL] [Abstract] [Full Text] [Related]
15. Differential proliferative index of cancer stem-like cells in primary and recurrent medulloblastoma in human.
Tang X; Yao Y; Zhu J; Jin K; Wang Y; Mao Y; Zhou L
Childs Nerv Syst; 2012 Nov; 28(11):1869-77. PubMed ID: 22814953
[TBL] [Abstract] [Full Text] [Related]
16. Polysialic acid neural cell adhesion molecule (psa-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines.
Amoureux MC; Coulibaly B; Chinot O; Loundou A; Metellus P; Rougon G; Figarella-Branger D
BMC Cancer; 2010 Mar; 10():91. PubMed ID: 20219118
[TBL] [Abstract] [Full Text] [Related]
17. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract] [Full Text] [Related]
18. Polysialic acid overexpression in malignant astrocytomas.
Petridis AK; Wedderkopp H; Hugo HH; Maximilian Mehdorn H
Acta Neurochir (Wien); 2009 Jun; 151(6):601-3; discussion 603-4. PubMed ID: 19387537
[TBL] [Abstract] [Full Text] [Related]
19. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract] [Full Text] [Related]
[Next]
